Statistik Botox 2026: Berapa Banyak Orang yang Melakukan Botox?

Halaman ini merupakan referensi tunggal untuk data terbaru mengenai Botox dan produk toksin botulinum serupa. Halaman ini mencakup berapa banyak perawatan yang dilakukan, negara mana yang paling banyak melakukan prosedur, siapa saja pasiennya, berapa biaya prosedurnya, bagaimana perubahan pasarnya, dan apa yang dinyatakan label FDA mengenai dosis serta efek sampingnya. “Botox” adalah nama merek. Kecuali dinyatakan lain, angka-angka tersebut mencakup semua produk toksin botulinum, yang terkadang disebut sebagai neuromodulator.

Kami terutama mengandalkan sumber primer: Survei Global International Society of Aesthetic Plastic Surgery (ISAPS), laporan tahunan American Society of Plastic Surgeons (ASPS), informasi peresepan FDA, laporan wabah CDC, jajak pendapat nasional oleh YouGov, dan hasil keuangan perusahaan. Setiap sumber mengukur sesuatu yang sedikit berbeda, jadi kami jelaskan di bawah ini dari mana angka-angka tersebut berasal dan mengapa angka-angka tersebut tidak selalu sama.

Sekilas Statistik Utama Botox

*Catatan Harga Penting (Syarat dan Ketentuan Berlaku): Biaya yang ditampilkan adalah rata-rata survei historis AS dari ASPS dan hanya merupakan estimasi pasar/perencanaan umum, bukan kutipan harga tetap rumah sakit atau klinik. Syarat dan ketentuan berlaku. Harga akhir hanya dapat dikonfirmasi setelah konsultasi dan pemeriksaan langsung di rumah sakit atau klinik, dan bisa lebih tinggi atau lebih rendah tergantung pada area yang dirawat, jumlah unit, dan kompleksitas individu.

Cara Mengutip Halaman Ini

Anda dipersilakan untuk menggunakan angka apa pun di halaman ini. Harap tautkan ke halaman ini dan, jika memungkinkan, ke sumber asli yang tercantum di samping setiap angka.

Saran sitasi: BeautsGO (beautsgo.beauty). “Statistik Botox 2026: Berapa Banyak Orang yang Melakukan Botox?” https://beautsgo.beauty/blogs/botox-statistics/

Berapa Banyak Orang yang Melakukan Botox Setiap Tahun?

Dokter bedah plastik di seluruh dunia melakukan 7.333.647 perawatan toksin botulinum pada tahun 2025, turun 7,0% dari 7.887.955 pada tahun 2024 namun naik 0,3% dari tahun 2021 (ISAPS 2025). Ini adalah prosedur kosmetik yang paling umum dilakukan, baik bedah maupun non-bedah, serta perawatan non-bedah yang paling umum bagi wanita maupun pria di setiap kelompok usia.

Ini adalah jumlah perawatan, bukan jumlah orang. Banyak pasien melakukan Botox dua atau tiga kali setahun, sehingga jumlah orang yang dirawat lebih rendah daripada jumlah perawatan.

Botox di Amerika Serikat

American Society of Plastic Surgeons memperkirakan terdapat 9.883.711 perawatan neuromodulator di AS pada tahun 2024, naik 4% dari 9.480.949 pada tahun 2023 dan 8.736.591 pada tahun 2022. Untuk tahun 2025, ASPS hanya memublikasikan pangsa: neuromodulator mencakup sekitar setengah dari semua prosedur kosmetik invasif minimal, dan filler asam hialuronat mencakup 30% lainnya (laporan ASPS 2025).

Mengapa Angka ISAPS dan ASPS Berbeda

ISAPS mencatat 1,46 juta perawatan di AS; ASPS mencatat 9,88 juta. Mereka mengukur hal yang berbeda:

Neither covers every injector. Nurses, medical spas and other doctors give a large share of Botox, so both figures probably undercount total use. When you quote a number, name the source.

Which Countries Do the Most Botox?

The United States performs the most botulinum toxin treatments, followed by China and South Korea.

Source: ISAPS International Survey 2025, page 80.

Botox per Capita by Country

Per person, Greece and South Korea lead by a wide margin.

Our calculation: ISAPS 2025 botulinum toxin treatments by country divided by UN World Population Prospects 2024 population for mid-2025.

Botulinum toxin is the most common non-surgical treatment in almost every surveyed country. In South Korea it is 47.4% of all non-surgical procedures by plastic surgeons. Low figures in some countries, such as the UK and India, mostly reflect that Botox there is usually given by doctors other than plastic surgeons, whom ISAPS does not count. For the wider picture, see our Korean beauty industry statistics.

What Percentage of Women Get Botox?

There is no nationally representative survey that measures how many women have ever had Botox. The best available polls suggest it is a small minority of women, although many more are open to it.

The widely shared claim that “42% of women get Botox” comes from a self-selected magazine poll of about 200 women aged 30 to 45, so it does not describe women in general.

What the procedure data does show is that Botox patients are overwhelmingly women: 84.6% of treatments worldwide (ISAPS 2025) and 94% in the US (ASPS 2024).

Botox and Men

Men received about 15% of botulinum toxin treatments worldwide in 2025 (1.13 million, our calculation from ISAPS). In the US, men had 593,854 neuromodulator treatments in 2024, about 6% of the total and up 4.3% (ASPS). Botox is the most popular non-surgical treatment for men as well as women.

Botox by Age

Source: ISAPS 2025, page 107.

In the US, 57% of neuromodulator treatments in 2024 were for patients aged 40 to 54 (ASPS). Interest among younger people is rising: 57% of facial plastic surgeons said more patients under 30 were asking for injectables or other cosmetic procedures in 2025 (AAFPRS, Feb 2026).

Is Botox Becoming Less Popular?

Botox-type treatments are still the world’s most popular cosmetic procedure, but 2025 was a softer year, and the Botox brand is losing ground to rivals.

• Volume: worldwide treatments by plastic surgeons fell 7.0% in 2025, as part of a wider 15.7% fall in non-surgical procedures (ISAPS 2025).
• Botox brand: AbbVie’s global Botox Cosmetic revenue fell 4.3% to $2.602 billion in 2025. US revenue fell 10.5% to $1.504 billion while international revenue rose 5.7%.
• Competitors are growing: Galderma’s neuromodulator sales (mainly Dysport) rose 14.3% at constant currency to $1.471 billion, and Evolus (Jeuveau) grew total revenue 12% to $297.2 million (Galderma; Evolus).

So a fall in Botox brand sales does not by itself mean fewer people are getting toxin treatments.

Botox vs Dysport, Xeomin, Jeuveau, Daxxify and Letybo

Sources: FDA approval letters on accessdata.fda.gov. Relfydess (Galderma) is approved in other countries but not in the US as of October 2026.

How Much Does Botox Cost?

The average US physician fee for neuromodulator injections was $435 per treatment in 2023, according to ASPS, down from $528 in 2022. The Aesthetic Society’s billing data put the average charge at $326 per treatment in 2022.

2023 is the latest year ASPS published a neuromodulator fee. Fees vary by area treated, number of units, city and provider, and exclude any facility charges.

*Important Pricing Note (Terms and Conditions Apply): These figures are historical US survey and billing averages and are general market/planning estimates only, not fixed hospital or clinic quotations. Terms and conditions apply. The final price can only be confirmed after an in-person consultation and examination at the hospital or clinic, and may be higher or lower depending on the areas treated, number of units, product used and individual complexity.

For treatment options and prices in Korea, see Botox in Korea dan aesthetic dermatology clinics.

How Many Units of Botox Are Used?

The FDA-approved doses of Botox Cosmetic are set by treatment area. Your injector decides the actual dose.

Source: Botox Cosmetic prescribing information, revised October 2024. The label says treatment more often than every 3 months has not been shown to be safe and effective. Units are not interchangeable between brands.

Korean Botulinum Toxin Brands

Korea has its own botulinum toxin industry, and Korean-made brands such as Botulax (Hugel), Nabota (Daewoong) and Meditoxin (Medytox) are widely used at home and exported. Two of them are now FDA-approved in the US: Daewoong’s toxin as Jeuveau (2019) and Hugel’s as Letybo (2024).

• Hugel’s 2025 toxin sales were KRW 233.8 billion, and Daewoong’s Nabota sold KRW 228.9 billion.
• Korea exported US$430 million of toxins and toxoids, the customs category that includes botulinum toxin, in January to September 2026, up 43.1% (KHIDI, via Medipana).

Many visitors to Seoul combine toxin treatments with skin treatments; see why some people spend more on skin boosters than fillers dan skin boosters.

How Big Is the Botox Market?

The clearest figures come from company results. AbbVie’s Botox Cosmetic earned $2.602 billion in 2025. Its medical version, Botox Therapeutic, used for conditions such as chronic migraine, earned more: $3.769 billion, up 14.8%. Galderma’s neuromodulators earned $1.471 billion.

Market research firms publish wider estimates for all botulinum toxin products, cosmetic and medical. Their totals vary by definition, so use company revenue for the cosmetic market where possible.

Is Botox Safe? What the Data Shows

• Clinical trial side effects: in the FDA label, eyelid drooping affected 3% of patients treated for frown lines (0% on placebo), eyelid swelling 1% for crow’s feet, and headache 9% for forehead lines (5% on placebo).
• Boxed warning: the label warns that toxin effects can spread beyond the injection site, causing swallowing and breathing problems that can be life-threatening.
• Botox Palsu: pada tahun 2023 dan 2024, CDC mengaitkan 17 kasus reaksi berbahaya di 9 negara bagian AS dengan toksin palsu atau yang tidak ditangani dengan benar; 13 orang dirawat di rumah sakit dan 6 orang diobati dengan antitoksin botulisme. Suntikan tersebut diberikan oleh orang yang tidak berlisensi atau tidak terlatih, atau di lingkungan non-medis seperti rumah dan spa (CDC). Pada tahun 2025, tiga wanita dirawat di rumah sakit setelah menyuntikkan toksin yang mereka beli secara daring dari penjual di Asia (CDC MMWR, 2025).

FDA menyatakan bahwa penyakit tahun 2024 tidak terkait dengan Botox asli yang disetujui FDA. Pilihlah penyedia layanan medis berlisensi yang menggunakan produk resmi. Baca lebih lanjut mengenai apakah wisata medis itu aman.

Metodologi dan Sumber

• Angka global dan negara berasal dari ISAPS International Survey 2025, yang memproyeksikan total nasional dari survei terhadap dokter bedah plastik dan hanya menghitung prosedur yang mereka lakukan.
• Angka AS berasal dari ASPS. Metode penghitungannya telah berubah dari waktu ke waktu, sehingga perbandingan jangka panjang tidak bersifat setara. ASPS tidak memublikasikan jumlah neuromodulator tahun 2025.
• Tingkat per kapita adalah perhitungan kami menggunakan UN World Population Prospects 2024 (pertengahan 2025).
• Jajak pendapat merupakan panel daring berbobot, bukan sampel probabilitas, dan redaksi pertanyaan berbeda-beda.
• Pendapatan perusahaan berasal dari rilis hasil AbbVie, Galderma, Evolus, dan Hugel.

Sumber

1. Survei Internasional ISAPS mengenai Prosedur Estetika/Kosmetik 2025. isaps.org
2. Laporan statistik American Society of Plastic Surgeons tahun 2024 dan 2025. plasticsurgery.org
3. Survei Yahoo News/YouGov, 20 hingga 24 Maret 2025. PDF YouGov
4. Jajak pendapat standar kecantikan YouGov, Februari 2026. PDF YouGov
5. YouGov Australia, Januari 2024. yougov.com
6. Hasil setahun penuh AbbVie 2025, 4 Februari 2026. abbvie.com
7. Hasil Galderma 2025, Maret 2026. galderma.com
8. Hasil Evolus 2025, pengajuan SEC, Maret 2026. sec.gov
9. Informasi peresepan Botox Cosmetic, US FDA, Oktober 2024. accessdata.fda.gov
10. CDC, reaksi berbahaya terkait dengan Botox palsu, 2024. cdc.gov
11. CDC MMWR, botulisme setelah penyuntikan mandiri toksin yang dibeli secara daring, 2025. cdc.gov
12. American Academy of Facial Plastic and Reconstructive Surgery, survei tren 2025. aafprs.org
13. Data ekspor toksin dari Korea Health Industry Development Institute, melalui Medipana. medipana.com